Category: Pfizer

Pfizer And Merck Go For An Even Longer Throw Of The Javelin

Pfizer and Merck KGaA’s tweaks to the Javelin Lung 100 study of their PD-L1 antibody avelumab, which will delay its readout by almost two years, look like a painful but necessary adjustment to commercial realities in this competitive cancer indication. The changes will more than double the size of the study, in first-line non-small cell lung cancer, and push data out to mid-2019.

Pfizer Subpoenaed in DOJ Investigation of Drugmaker Charity Connections

Pfizer Inc. said that it received two subpoenas from the U.S. Attorney’s office in Massachusetts related to charities that help Medicare patients afford co-payments for drugs, the latest company to disclose involvement in the probe. The New York-based drugmaker said in a securities filing Thursday that it received subpoenas on December 2015 and on July 2016 requesting documents related to the Patient Access Network Foundation and other organizations that provide financial assistance to Medicare patients.

ViiV Healthcare announces detailed positive phase III results for…

In the SWORD studies, the two-drug regimen showed comparable efficacy to three- or four-drug regimensin virologically suppressed patients. ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir and rilpivirine .

Global Auto-Injector Market is Expected to Grow at CAGR 18% and USD 2.9 Billion By 2022

Auto-Injector Device Market Expected To Grow At the CAGR of ~18%, Auto-Injector Market Size Is Expected To Increase by USD 2.9 Billion by the End of 2022 Key Players – SHL Group , Jiangsu Delfu medical device Co., Ltd , Becton, Dickinson and Company , Novartis International AG , Pfizer Inc., Ypsomed Holding AG , Unilife Corporation and Owen Mumford” PUNE, MAHARASTRA, INDIA, February 1, 2017 / EINPresswire.com / — Market Highlights Auto-Injector Market has been evaluated to be rapidly growing and expected to maintain this growth rate. Moreover, there is a huge possibility that the market will grow further in future.

Pfizer Seeks Deals as Generic Versions Hurts Older Drugs’ Sales

Pfizer Inc. expects more generic competition for its established drugs in 2017, and the company’s deal-making to gain products may continue to thrive. After posting fourth-quarter earnings and a forecast that were short of analysts’ estimates, New York-based Pfizer said it would continue to pursue deals, regardless of their size, as long as they create shareholder value.

Dow 30 Earnings: Pfizer Fourth Quarter 2016

… quarter of 2015 had a negative impact of roughly $750 million. On the operating front, the company’s Innovative Health segment, which sells newer, patent-protected drugs, contributed sales of $7.7 billion (+1%), driven by continued growth of …

What Will You Hear on Pfizer’s Fourth-Quarter Call Tuesday?

What’s likely to be at the top of investors’ minds during Pfizer’s fourth-quarter conference call Tuesday morning? How about Pfizer’s plans to overcome oncoming competition involving several important products while navigating what remains a difficult pricing environment? Clues from CEO Ian Read and the management team about the company’s capital deployment plans ought to be of high interest, too. In the wake of continued speculation around the sale of its consumer business, which operates as part of its Innovative Health segment and is home to the Chapstick and Advil brands, potential strategic M&A and divestitures could make up for slowing revenue growth seen across existing therapies.

This Dividend Anchor Could Return More Than 23% In 2017

Pfizer has been on a roll lately, recently announcing successful top-line results for its third biosimilar in the last four months. The success of its biosimilar initiatives could potentially give Pfizer a secure foothold in the biosimilars market, which could grow to $20 billion in just three years.

Press release distribution, EDGAR filing, XBRL, regulatory filings

Pfizer Receives Approval in the European Union for Nimenrix in Infants Six Weeks of Age and Older )–Pfizer Inc. announced today the European Commission has approved an expanded indication for Nimenrixa Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express High Levels of PD-L1 )–KEYTRUDA Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express H… )–Madame Tussauds and country superstar Brad Paisley joined forces to pay tribute to Grand Ole Opry legend Little Jimmy Dickens by unveiling his wax figure on the R… )–Manitowoc Foodservice announces SVP, General Counsel and Secretary Maurice Jones retirement; promotes Joel Horn to SVP, General Counsel and Secretary effecti… )–Mitsubishi UFJ Capital, a … (more)